Vigilant Biosciences recently introduced the OncAlert Labs OraMark Test, which is described as the first quantitative oral rinse test to accurately measure a tumor-initiating and stem cell associated biomarker for oral cancer detection at its earliest stages.
OraMark will be available to U.S. clinicians as a laboratory developed test in the second half of 2016, according to a press release. OraMark is based on patented technology that includes advanced methods for measuring the tumor-initiating and stem cell associated biomarker CD44 in combination with total protein. This is said to enable earlier and more accurate detection of oral cancer.
The test offers actionable information pre- and post-biopsy, which complements visual examination and other tools used by head and neck specialists for detecting oral cancer. It reportedly optimizes management and surveillance to lead to more successful outcomes.
To complete the test, an easy-to-collect oral rinse is sent to OncAlert Labs for analysis. The test is cost-effective and easy to administer. It’s also non-invasive and provides results that are easy for clinicians to interpret.
View Full Press Release
Source: Vigilant Biosciences